Cargando…

Update on Statin Treatment in Patients with Neuropsychiatric Disorders

Statins are widely accepted as first-choice agents for the prevention of lipid-related cardiovascular diseases. These drugs have both anti-inflammatory and anti-oxidant properties, which may also make them effective as potential treatment marked by perturbations in these pathways, such as some neuro...

Descripción completa

Detalles Bibliográficos
Autores principales: Avan, Razieh, Sahebnasagh, Adeleh, Hashemi, Javad, Monajati, Mahila, Faramarzi, Fatemeh, Henney, Neil C., Montecucco, Fabrizio, Jamialahmadi, Tannaz, Sahebkar, Amirhossein
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703562/
https://www.ncbi.nlm.nih.gov/pubmed/34947895
http://dx.doi.org/10.3390/life11121365
_version_ 1784621493567619072
author Avan, Razieh
Sahebnasagh, Adeleh
Hashemi, Javad
Monajati, Mahila
Faramarzi, Fatemeh
Henney, Neil C.
Montecucco, Fabrizio
Jamialahmadi, Tannaz
Sahebkar, Amirhossein
author_facet Avan, Razieh
Sahebnasagh, Adeleh
Hashemi, Javad
Monajati, Mahila
Faramarzi, Fatemeh
Henney, Neil C.
Montecucco, Fabrizio
Jamialahmadi, Tannaz
Sahebkar, Amirhossein
author_sort Avan, Razieh
collection PubMed
description Statins are widely accepted as first-choice agents for the prevention of lipid-related cardiovascular diseases. These drugs have both anti-inflammatory and anti-oxidant properties, which may also make them effective as potential treatment marked by perturbations in these pathways, such as some neuropsychiatric disorders. In this narrative review, we have investigated the effects of statin therapy in individuals suffering from major depressive disorder (MDD), schizophrenia, anxiety, obsessive-compulsive disorder (OCD), bipolar disorder (BD), delirium, and autism spectrum disorders using a broad online search of electronic databases. We also explored the adverse effects of these drugs to obtain insights into the benefits and risks associated with their use in the treatment of these disorders. Lipophilic statins (including simvastatin) because of better brain penetrance may have greater protective effects against MDD and schizophrenia. The significant positive effects of statins in the treatment of anxiety disorders without any serious adverse side effects were shown in numerous studies. In OCD, BD, and delirium, limitations, and contradictions in the available data make it difficult to draw conclusions on any positive effect of statins. The positive effects of simvastatin in autism disorders have been evaluated in only a small number of clinical trials. Although some studies showed positive effect of statins in some neuropsychiatric disorders, further prospective studies are needed to confirm this and define the most effective doses and treatment durations.
format Online
Article
Text
id pubmed-8703562
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-87035622021-12-25 Update on Statin Treatment in Patients with Neuropsychiatric Disorders Avan, Razieh Sahebnasagh, Adeleh Hashemi, Javad Monajati, Mahila Faramarzi, Fatemeh Henney, Neil C. Montecucco, Fabrizio Jamialahmadi, Tannaz Sahebkar, Amirhossein Life (Basel) Review Statins are widely accepted as first-choice agents for the prevention of lipid-related cardiovascular diseases. These drugs have both anti-inflammatory and anti-oxidant properties, which may also make them effective as potential treatment marked by perturbations in these pathways, such as some neuropsychiatric disorders. In this narrative review, we have investigated the effects of statin therapy in individuals suffering from major depressive disorder (MDD), schizophrenia, anxiety, obsessive-compulsive disorder (OCD), bipolar disorder (BD), delirium, and autism spectrum disorders using a broad online search of electronic databases. We also explored the adverse effects of these drugs to obtain insights into the benefits and risks associated with their use in the treatment of these disorders. Lipophilic statins (including simvastatin) because of better brain penetrance may have greater protective effects against MDD and schizophrenia. The significant positive effects of statins in the treatment of anxiety disorders without any serious adverse side effects were shown in numerous studies. In OCD, BD, and delirium, limitations, and contradictions in the available data make it difficult to draw conclusions on any positive effect of statins. The positive effects of simvastatin in autism disorders have been evaluated in only a small number of clinical trials. Although some studies showed positive effect of statins in some neuropsychiatric disorders, further prospective studies are needed to confirm this and define the most effective doses and treatment durations. MDPI 2021-12-08 /pmc/articles/PMC8703562/ /pubmed/34947895 http://dx.doi.org/10.3390/life11121365 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Avan, Razieh
Sahebnasagh, Adeleh
Hashemi, Javad
Monajati, Mahila
Faramarzi, Fatemeh
Henney, Neil C.
Montecucco, Fabrizio
Jamialahmadi, Tannaz
Sahebkar, Amirhossein
Update on Statin Treatment in Patients with Neuropsychiatric Disorders
title Update on Statin Treatment in Patients with Neuropsychiatric Disorders
title_full Update on Statin Treatment in Patients with Neuropsychiatric Disorders
title_fullStr Update on Statin Treatment in Patients with Neuropsychiatric Disorders
title_full_unstemmed Update on Statin Treatment in Patients with Neuropsychiatric Disorders
title_short Update on Statin Treatment in Patients with Neuropsychiatric Disorders
title_sort update on statin treatment in patients with neuropsychiatric disorders
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8703562/
https://www.ncbi.nlm.nih.gov/pubmed/34947895
http://dx.doi.org/10.3390/life11121365
work_keys_str_mv AT avanrazieh updateonstatintreatmentinpatientswithneuropsychiatricdisorders
AT sahebnasaghadeleh updateonstatintreatmentinpatientswithneuropsychiatricdisorders
AT hashemijavad updateonstatintreatmentinpatientswithneuropsychiatricdisorders
AT monajatimahila updateonstatintreatmentinpatientswithneuropsychiatricdisorders
AT faramarzifatemeh updateonstatintreatmentinpatientswithneuropsychiatricdisorders
AT henneyneilc updateonstatintreatmentinpatientswithneuropsychiatricdisorders
AT montecuccofabrizio updateonstatintreatmentinpatientswithneuropsychiatricdisorders
AT jamialahmaditannaz updateonstatintreatmentinpatientswithneuropsychiatricdisorders
AT sahebkaramirhossein updateonstatintreatmentinpatientswithneuropsychiatricdisorders